A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks

Trial Profile

A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Besifovir (Primary) ; Levocarnitine; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Sponsors Ildong Pharmaceutical
  • Most Recent Events

    • 14 Apr 2018 Results over 96 week presented at The International Liver Congress 2018.
    • 19 Mar 2018 Planned End Date changed from 1 Jan 2016 to 1 Jan 2023.
    • 23 Apr 2017 Status changed from recruiting to active, no longer recruiting, according to results presented at The International Liver Congress 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top